Thu Sep 19 06:58:53 UTC 2024: ## OPKO Health Stock Receives “Overweight” Rating from Piper Sandler
**Miami, FL – September 19, 2024** – OPKO Health (NASDAQ:OPK), a healthcare company focused on diagnostics and pharmaceuticals, saw its stock receive an “overweight” rating from Piper Sandler in a report released Tuesday. The firm also set a price target of $3.00, representing a potential upside of 85.19% from the current stock price.
The positive outlook from Piper Sandler comes amidst mixed signals from other analysts. StockNews.com downgraded OPKO Health to a “sell” rating in July, while Barrington Research upgraded the stock to “outperform” with a $2.25 target price in August. HC Wainwright maintained a “buy” rating and a $3.00 price target.
OPKO Health’s recent earnings report, released on August 7th, showed a profit of $0.01 per share, beating analyst expectations. However, the company’s revenue fell by 31.3% year-over-year.
In other news, a major shareholder, Opko Health, Inc., sold 12,994 shares of the company’s stock in August, while institutional investors have been actively adjusting their positions. Notably, Rubric Capital Management LP significantly increased its stake in OPKO Health during the second quarter, while Y.D. More Investments Ltd and Squarepoint Ops LLC acquired new positions.
OPKO Health operates in the US, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostics segment includes BioReference Laboratories, providing lab testing services across various areas, including esoteric testing, molecular diagnostics, and women’s health.
The company’s future performance will depend on the success of its diagnostics and pharmaceuticals businesses and its ability to navigate the evolving healthcare landscape. Investors will be closely watching to see how OPKO Health performs in the coming months.
First Piper 